Cardiff Oncology Inc (CRDF) financials
Cardiff Oncology revenue and earnings by year
Cardiff Oncology's revenue was $593,000 in the fiscal year to December 31, 2025, down 13.2% from the year before. Net income was -$45.9 million, -7732.0% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 5.0% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Revenue growth | -13.2% | 40.0% | 26.4% | 7.5% | -1.9% | 49.6% | -35.3% | -25.1% | 32.6% | — |
| Gross profit | — | — | — | — | — | — | — | -0 | -1 | -1 |
| Gross margin | — | — | — | — | — | — | — | -57.9% | -258.4% | -354.1% |
| Operating income | -49 | -49 | -45 | -40 | -29 | -19 | -17 | -17 | -26 | -40 |
| Operating margin | -8256.3% | -7123.1% | -9305.7% | -10337.3% | -8037.6% | -5214.8% | -6817.0% | -4570.2% | -5064.4% | -10534.9% |
| Net income | -46 | -45 | -41 | -39 | -28 | -19 | -16 | -16 | -25 | -39 |
| Net margin | -7732.0% | -6651.7% | -8492.0% | -10026.9% | -7880.5% | -5275.1% | -6709.7% | -4351.1% | -4928.1% | -10287.7% |
| Diluted EPS | -$0.69 | -$0.95 | -$0.93 | -$0.89 | -$0.73 | — | — | -$8.26 | -$54.54 | -$99.36 |
| Free cash flow | -38 | -38 | -31 | -35 | -23 | -17 | -13 | -13 | -23 | -32 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open CRDF in Markets.
See also: CRDF returns
No forecast, no recommendation. This page describes Cardiff Oncology Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.